Lidak other research news

LDAKA presented its discovery of four peptides as potential agents to block early events in the inflammatory cascade mediated by complement. By using a new technology to which LDAKA has exclusive license, researchers associated with the company identified active sites in the complement proteins that were then targeted as sites for inhibition by designed peptides.

Reporting at the International Complement Workshop in Boston, the scientists showed that four peptides can suppress inflammatory responses by blocking interactions among complement proteins. LDAKA will pursue commercial development of the complement inhibitors as potential anti-inflammatory agents. ...